A better understanding of CD96 prognostic value in different cancer types as well as a better knowledge of CD96 signaling pathways in both NK cells and CD8+ T cells should help reconcile so far contradicting data and establish strategies to target this receptor in cancer patients. This evidence concerns the gene CD8A and cancer.